Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours

Lykoudis, Panagis M.; Partelli, Stefano; Muffatti, Francesca; Caplin, Martyn; Falconi, Massimo; Fusai, Giuseppe

doi:10.1016/j.ejso.2017.08.019

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As expected, due to the different etiology and biology of the PNET neoplasms [28,29], survival was much higher than for the rest of the study population (the non-PNETs). The 5-year RS for this subgroup was 61.45 (95% CI 47.47; 79.55), above those observed in Europe for the period 2000-2007: 42.9% (95% CI 41.0; 44.8) [30]. Following the whole series tendency, it improved thorough the study timeframe.…”

Section: Discussionmentioning

confidence: 50%

Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years

García-Velasco

Zacarías-Pons

Teixidor

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

(1) Background: We investigated the incidence and survival trends for pancreatic cancer (PC) over the last 25 years in the Girona region, Catalonia, Spain; (2) Methods: Data were extracted from the population-based Girona Cancer Registry. Incident PC cases during 1994–2015 were classified using the International Classification of Diseases for Oncology Third Edition (ICD-O-3). Incidence rates age-adjusted to the European standard population (ASRE) and world standard population (ASRW) were obtained. Trends were assessed using the estimated annual percentage of change (EAPC) of the ASRE13. Observed and relative survivals (RS) were estimated with the Kaplan–Meier and Pohar Perme methods, respectively; (3) Results: We identified 1602 PC incident cases. According to histology, 44.4% of cases were exocrine PC, 4.1% neuroendocrine, and 51.1% malignant-non-specified. The crude incidence rate (CR) for PC was 11.43 cases-per-100,000 inhabitants/year. A significant increase of incidence with age and over the study period was observed. PC overall 5-year RS was 7.05% (95% confidence interval (CI) 5.63; 8.84). Longer overall survival was observed in patients with neuroendocrine tumours (5-year RS 61.45%; 95% CI 47.47; 79.55). Trends in 5-year RS for the whole cohort rose from 3.27% (95% CI 1.69–6.35) in 1994–1998 to 13.1% (95% CI 9.98; 17.2) in 2010–2015; (4) Conclusions: Incidence rates of PC in Girona have increased in the last two decades. There is a moderate but encouraging increase in survival thorough the study period. These results can be used as baseline for future research.

show abstract

Section: Discussionmentioning

confidence: 50%

Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years

García-Velasco

Zacarías-Pons

Teixidor

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Pancreatic neuroendocrine tumors (PNET) are a rare disease with a significant malignant potential but with a better overall survival (OS) prognosis than that associated with adenocarcinoma or cholangiocarcinoma [ 1 – 3 ]. The steadily increasing incidence of PNET over the last 20 years has been attributed mainly to increased incidental detection during the performance of non-specific imaging [computed tomography (CT), magnetic resonance imaging (MRI), endoscopy ultrasound (EUS)].…”

Section: Introductionmentioning

confidence: 99%

A single-center experience with pancreatic cystic neuroendocrine tumors

Ewald

Marchese

et al. 2020

World J Surg Onc

View full text Add to dashboard Cite

Background: Pancreatic neuroendocrine tumors (PNET) are rare, with a significant malignant potential. This study aimed to determine outcomes of patients with resected PNETs according to the cystic component and confirm the accuracy of preoperative staging. Methods: From 1997 to 2016, 106 patients underwent resection of PNETs, including 73 purely solid (S-PNETs, 69%), 21 mixed (M-PNETs, 20%), and 12 purely cystic lesions (C-PNETs, 11%). To ensure consistent comparisons of overall (OS) and disease-free (DFS) survival outcomes between the 3 groups, the patients were matched according to the World Health Organization (WHO) grade and tumor height. Results: Overall, the rate of correlation between the preoperative and pathological diagnoses was low in the C-PNET group (33%, P = 0.03). None of the 24 patients (23%) with metastatic disease at the time of surgery were in the C-PNET group. Furthermore, significantly more parenchyma-sparing resections (P = 0.039) and fewer enlarged resections (P = 0.019) were achieved in the C-PNET group. C-PNET group had a significantly lower node invasion rate than the S-PNET and M-PNET groups (8% vs. 41% and 24%, P = 0.004). Although median OS was comparable in all 3 groups before (P = 0.3) and after (P = 0.18) matching, higher median DFS was observed in the C-PNET group than in the other groups after matching (P = 0.038). Conclusion: C-PNET was associated with a better prognosis than PNET with a solid component. The results support a wait-and-see policy in cases wherein a reliable preoperative diagnosis remains challenging.

show abstract

Central pancreatectomy with common hepatic artery resection for a giant pancreatic neuroendocrine tumor

KIROV¹

2022

Chirurgia

View full text Add to dashboard Cite

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours

Cited by 3 publications

References 30 publications

Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years

Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years

A single-center experience with pancreatic cystic neuroendocrine tumors

Central pancreatectomy with common hepatic artery resection for a giant pancreatic neuroendocrine tumor

Contact Info

Product

Resources

About